TWD 90.3
(-1.85%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 712.98 Million TWD | 27.93% |
2022 | 557.34 Million TWD | 10.25% |
2021 | 505.53 Million TWD | 8.28% |
2020 | 466.88 Million TWD | 6.62% |
2019 | 437.87 Million TWD | 32.86% |
2018 | 329.58 Million TWD | 27.54% |
2017 | 258.41 Million TWD | 13.19% |
2016 | 228.3 Million TWD | -13.8% |
2015 | 264.84 Million TWD | 67.32% |
2014 | 158.28 Million TWD | -21.06% |
2013 | 200.5 Million TWD | -0.09% |
2012 | 200.68 Million TWD | 40.07% |
2011 | 143.27 Million TWD | 116.37% |
2010 | 66.21 Million TWD | 322.24% |
2009 | 15.68 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 195.35 Million TWD | -3.88% |
2024 Q2 | 210.55 Million TWD | 7.78% |
2023 Q1 | 120.37 Million TWD | -24.7% |
2023 FY | 712.98 Million TWD | 27.93% |
2023 Q4 | 203.24 Million TWD | -1.38% |
2023 Q3 | 206.09 Million TWD | 12.46% |
2023 Q2 | 183.26 Million TWD | 52.24% |
2022 FY | 557.34 Million TWD | 10.25% |
2022 Q4 | 159.86 Million TWD | -3.05% |
2022 Q3 | 164.9 Million TWD | 24.73% |
2022 Q2 | 132.21 Million TWD | 31.73% |
2022 Q1 | 100.36 Million TWD | -28.43% |
2021 FY | 505.53 Million TWD | 8.28% |
2021 Q1 | 111.23 Million TWD | -15.69% |
2021 Q2 | 126.8 Million TWD | 14.0% |
2021 Q3 | 127.26 Million TWD | 0.37% |
2021 Q4 | 140.23 Million TWD | 10.19% |
2020 FY | 466.88 Million TWD | 6.62% |
2020 Q1 | 109.81 Million TWD | -15.4% |
2020 Q2 | 104.18 Million TWD | -5.13% |
2020 Q3 | 120.96 Million TWD | 16.11% |
2020 Q4 | 131.92 Million TWD | 9.07% |
2019 Q2 | 100.81 Million TWD | -3.47% |
2019 FY | 437.87 Million TWD | 32.86% |
2019 Q4 | 129.81 Million TWD | 26.26% |
2019 Q3 | 102.81 Million TWD | 1.98% |
2019 Q1 | 104.43 Million TWD | 2.76% |
2018 Q2 | 50.7 Million TWD | -51.29% |
2018 FY | 329.58 Million TWD | 27.54% |
2018 Q3 | 73.15 Million TWD | 44.29% |
2018 Q4 | 101.63 Million TWD | 38.92% |
2018 Q1 | 104.08 Million TWD | 20.28% |
2017 Q3 | 54.45 Million TWD | -20.47% |
2017 FY | 258.41 Million TWD | 13.19% |
2017 Q2 | 68.46 Million TWD | 39.82% |
2017 Q1 | 48.96 Million TWD | -32.01% |
2017 Q4 | 86.53 Million TWD | 58.92% |
2016 Q2 | 49.16 Million TWD | 7.2% |
2016 Q3 | 61.25 Million TWD | 24.6% |
2016 Q4 | 72.02 Million TWD | 17.57% |
2016 FY | 228.3 Million TWD | -13.8% |
2016 Q1 | 45.86 Million TWD | -26.1% |
2015 Q2 | 61.23 Million TWD | 1.62% |
2015 Q4 | 62.06 Million TWD | -23.65% |
2015 FY | 264.84 Million TWD | 67.32% |
2015 Q1 | 60.25 Million TWD | 75.03% |
2015 Q3 | 81.29 Million TWD | 32.76% |
2014 Q2 | 44.77 Million TWD | 18.92% |
2014 FY | 158.28 Million TWD | -21.06% |
2014 Q4 | 34.42 Million TWD | -16.92% |
2014 Q3 | 41.43 Million TWD | -7.45% |
2014 Q1 | 37.64 Million TWD | -25.83% |
2013 Q2 | 51.04 Million TWD | 15.81% |
2013 Q4 | 50.75 Million TWD | -7.1% |
2013 FY | 200.5 Million TWD | -0.09% |
2013 Q1 | 44.07 Million TWD | -41.89% |
2013 Q3 | 54.63 Million TWD | 7.05% |
2012 Q4 | 75.84 Million TWD | 40.29% |
2012 Q3 | 54.06 Million TWD | 37.23% |
2012 Q1 | 31.38 Million TWD | -24.53% |
2012 Q2 | 39.39 Million TWD | 25.53% |
2012 FY | 200.68 Million TWD | 40.07% |
2011 Q3 | 40.4 Million TWD | 0.0% |
2011 FY | 143.27 Million TWD | 116.37% |
2011 Q4 | 41.58 Million TWD | 2.91% |
2011 Q2 | - TWD | 0.0% |
2010 FY | 66.21 Million TWD | 322.24% |
2010 Q4 | - TWD | 0.0% |
2009 FY | 15.68 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 2.15 Billion TWD | 66.841% |
Maxigen Biotech Inc. | 622.11 Million TWD | -14.607% |
Bionime Corporation | 1.75 Billion TWD | 59.387% |
Pegavision Corporation | 6.78 Billion TWD | 89.499% |
Visco Vision Inc. | 2.39 Billion TWD | 70.263% |